
    
      This is a phase II, open-label, single-arm, multicenter study conducted in adult subjects
      with R/R Non-Hodgkins Lymphoma in China to evaluate the safety, efficacy,
      pharmacokinetics(PK), pharmacodynamics(PD) of JWCAR029 and collect the patient reported
      quality of life changes and immune response after JWCAR029 treatment.

      There will be two cohorts of cohort A and cohort B. Large B cell lymphoma (LBCL) patients
      will be enrolled in cohort A and follicular lymphoma patients will be enrolled in cohort B.
      Two dose levels of 1.0 x 10^8 CAR+ T cells and 1.5 x 10^8 CAR+ T cells are adopted in this
      study in both cohorts, subjects will be randomly assigned into the two dose levels with a 1:1
      ratio. All sujects will be followed for 2 years following JWCAR029 infusion.
    
  